This site is intended for US healthcare professionals only.

Ordering Information

For the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement

Important Safety Information and Indications

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.

How to Order

We have partnered with select specialty distributors to help ensure access to OTIPRIO

Ordering information

Wholesaler/
Distributor
Item Order
Number
Contact
Information
ASD Specialty Healthcare* 46146 Tel #: 1-800-746-6273
Fax #: 1-800-547-9413

Web Order URL:
asd.customerservice
@asdhealthcare.com

Besse Medical 46146 Tel #: 1-800-543-2111
Fax #: 1-800-543-8695

Web Order URL:
www.besse.com

Cardinal Health Specialty Distribution 5216924 Tel #: 1-866-677-4844
Fax #: 1-888-345-4916
Web Order URL:
specialtyonline.
cardinalhealth.com

orderexpress.
cardinalhealth.com
Henry Schein 124-8971 Tel #: 1-800-772-4346
Fax #: 1-800-329-9109
Web Order URL:
www.henryschein.com
/medical
McKesson Plasma and Biologics 3518339 Tel #: 1-877-625-2566
Fax #: 1-888-752-7626
Web Order URL:
connect.
mckesson.com
McKesson Medical-Surgical 1010433 Tel #: 1-866-625-2679
Fax #: Not available
Web Order URL:
mms.mckesson.com
NDC# Product Unit Qty
69251-201-01 Each OTIPRIO carton contains 1 mL of 6% (60 mg/mL, w/v) ciprofloxacin in a 2 mL single-patient use vial fitted with a rubber stopper One (1) box contains one single-patient use vial

OTIPRIO vial and package

Additional support

For additional support or questions, please contact Otonomy Answers by phone at 1-844-684-7746.

Assistance is available Monday through Friday, 8:00 AM – 8:00 PM ET, excluding major holidays.

 

  • *For customers of AmerisourceBergen Corporation full-line wholesale division, OTIPRIO is available through ASD Healthcare and can be ordered using the PassPort ordering platform through AmerisourceBergen.
  • For customers of Cardinal Health full-line wholesale division, OTIPRIO is available for purchase through Cardinal Health Specialty Distribution.
  • For customers of McKesson full-line wholesale division, OTIPRIO is available for purchase through McKesson Plasma and Biologics and McKesson Specialty Health.

 

DISCLAIMER:
This guide is intended solely for educational purposes regarding possible codes to report for use of OTIPRIO. The information provided contains general reimbursement information only and represents Otonomy’s understanding of current reimbursement policies as of January 1, 2017. Information should not be construed as legal advice nor is it advice about how to code, complete, or submit any particular claim for payment. Coding and reimbursement information is subject to change. Information provided is not intended to increase or maximize reimbursement by any payer.

Otonomy disclaims any responsibility for claims submitted by providers or physicians. The key in all coding and billing to payers is to be truthful and not misleading and make full disclosures to the payer about the product and the procedures associated with its use when seeking reimbursement for any product or procedure. It is the provider’s and physician’s responsibility to determine appropriate codes, charges, and modifiers, and to submit bills for services and products consistent with what was rendered as well as the patient’s insurer requirements. Third-party payers may have different coverage and reimbursement policies and coding requirements. Such policies can change over time. Providers are encouraged to contact third-party payers for each patient to verify specific information on their coding policies.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.

WARNINGS AND PRECAUTIONS

Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.

ADVERSE REACTIONS

Adverse reactions (incidence at least 3%) that occurred in two Phase 3 trials with OTIPRIO vs sham were: nasopharyngitis (5% vs 4%), irritability (5% vs 3%), and rhinorrhea (3% vs 2%).

USE IN SPECIFIC POPULATIONS

Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.

Indications and Usage

OTIPRIO® (ciprofloxacin otic suspension) 6% is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.

Please see full Prescribing Information.